Ramucirumab for advanced gastric cancer or gastro-oesophageal junction adenocarcinoma

被引：23
|
作者：
Young, Kate [1 ]
Smyth, Elizabeth [1 ]
Chau, Ian [1 ]
机构：
[1] Royal Marsden Hosp, Gastrointestinal Oncol Unit, Sutton SM2 5PT, Surrey, England
来源：
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY | 2015年 / 8卷 / 06期
关键词：
angiogenesis; gastric cancer; gastro-oesophageal cancer; ramucirumab; vascular endothelial growth factor; vascular endothelial growth factor receptor 2; RANDOMIZED PHASE-III; 2ND-LINE CHEMOTHERAPY; 1ST-LINE THERAPY; SUPPORTIVE CARE; DOUBLE-BLIND; OPEN-LABEL; GROWTH; COMBINATION; PLUS; VEGF;
D O I：
10.1177/1756283X15592586
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Ramucirumab, a fully humanized monoclonal antibody directed against vascular endothelial growth factor receptor 2, is the first targeted agent to have demonstrated an improvement in survival, as a single agent or in combination, in a molecularly unselected population in gastro-oesophageal cancer. Now that second-line treatment is routinely considered for patients with advanced gastro-oesophageal cancer, ramucirumab, with its favourable toxicity profile compared with cytotoxic treatment, provides a valuable additional treatment option.
引用
收藏
页码：373 / 383
页数：11
相关论文
共 50 条
  • [31] OBSTRUCTION OF THE GASTRO-OESOPHAGEAL JUNCTION
    ALLISON, PR
    LANCET, 1949, 257 (JUL16): : 91 - 94
  • [32] CROSS versus modified MAGIC or FLOT in oesophageal and gastro-oesophageal junction adenocarcinoma
    van Rossum, Peter S. N.
    van Laarhoven, Hanneke W. M.
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2023, 8 (11): : 959 - 960
  • [33] Cost-Effectiveness of ramucirumab plus paclitaxel as a second-line therapy for advanced gastric or gastro-oesophageal cancer in China
    Li, Sini
    Peng, Liubao
    Tan, Chongqing
    Zeng, Xiaohui
    Wan, Xiaomin
    Luo, Xia
    Yi, Lidan
    Li, Jianhe
    PLOS ONE, 2020, 15 (05):
  • [34] Systemic inflammatory markers and outcome in patients with locally advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction
    Jagadesham, V. P.
    Lagarde, S. M.
    Immanuel, A.
    Griffin, S. M.
    BRITISH JOURNAL OF SURGERY, 2017, 104 (04) : 401 - 407
  • [35] Different effects of esomeprazol on gastric and gastro-oesophageal junction PH
    Boecxstaens, V.
    Blondeau, K.
    Tack, J.
    NEUROGASTROENTEROLOGY AND MOTILITY, 2012, 24 : 165 - 165
  • [36] CEF chemotherapy for advanced gastro-oesophageal cancer
    Lacko, A
    Woll, PJ
    Langley, RE
    Thomas, A
    Carmichael, J
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 1272 - 1272
  • [37] A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma
    Scott, L. C.
    Yao, J. C.
    Benson, A. B., III
    Thomas, A. L.
    Falk, S.
    Mena, R. R.
    Picus, J.
    Wright, J.
    Mulcahy, M. F.
    Ajani, J. A.
    Evans, T. R. J.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 63 (02) : 363 - 370
  • [38] A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma
    L. C. Scott
    J. C. Yao
    A. B. Benson
    A. L. Thomas
    S. Falk
    R. R. Mena
    J. Picus
    J. Wright
    M. F. Mulcahy
    J. A. Ajani
    T. R. J. Evans
    Cancer Chemotherapy and Pharmacology, 2009, 63 : 363 - 370
  • [39] A PHASE I TRIAL OF BORTEZOMIB IN COMBINATION WITH EPIRUBICIN, CARBOPLATIN AND CAPECITABINE (ECARBOX) IN ADVANCED GASTRIC AND GASTRO-OESOPHAGEAL JUNCTION (GOJ) ADENOCARCINOMA
    Turkington, R. C.
    Purcell, C.
    Wilson, R. H.
    Eatock, M. M.
    ANNALS OF ONCOLOGY, 2012, 23 : 249 - 249
  • [40] Neoadjuvant chemotherapy in "technically" inoperable locally advanced oesophageal (0) and gastro-oesophageal junction (GOJ) cancer
    Cheong, KA
    Chrystal, K
    Forshaw, M
    Gossage, J
    Galani, E
    Botha, A
    Mason, R
    Harper, PG
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 347S - 347S
12345